key: cord-0869252-iu1pr4d1 authors: Rife Magalis, B.; Mavian, C.; Tagliamonte, M.; Rich, S.; Cash, M.; Riva, A.; Loeb, J. C.; Norris, M.; Moraga, D.; Zhang, Y.; Shapiro, J.; Starostik, P.; Marini, S.; Myers, P.; Ostrov, D. A.; Lednicky, J. A.; Morris, J. G.; Lauzardo, M.; Salemi, M. title: SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments date: 2021-05-21 journal: nan DOI: 10.1101/2021.05.19.21257237 sha: b5b0676d394c93cf9c34bbf84351591888c99e58 doc_id: 869252 cord_uid: iu1pr4d1 The emergence of SARS-CoV-2 variants of concern (VOC) has raised questions regarding the extent of protection of currently implemented vaccines. Ten "vaccination breakthrough" infections were identified in Alachua County, Florida, among individuals fully vaccinated with the BNT162b2 mRNA vaccine as a result of social or household transmission. Eight individuals presented mild symptoms in the absence of infection with other common respiratory viruses, confirmed using viral genetic sequencing. SARS-CoV-2 genomes were successfully generated for five of the vaccine breakthroughs and 399 individuals in the surrounding area and were included for reference-based phylogenetic investigation. These five individuals were characterized by infection with both VOCs and low-frequency variants present within the surrounding population. Mutations in the Spike protein were consistent with their respective circulating lineages, with the exception of a viable, low-frequency (approximately 1%) B.1.1.7 mutation, which we describe as a mutation of potential concern. The findings indicate that in cases of limited vaccine protection, infection is not restricted to VOCs or high-risk settings, highlighting the critical need for continued testing and monitoring of infection among individuals regardless of vaccination status. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 healthcare-related (80%), including students working in patient care. Contact tracing revealed that seven of these individuals had exposures to individuals previously identified as exposure in the workplace. So, despite healthcare workers increased risk of exposure, infection 82 in these individuals was likely the result of inadvertent exposure during social contact. Saliva samples were collected from the ten vaccine-breakthrough individuals within 3-7 days of 85 testing positive for infection (Tables 1 and S1). Saliva collection was used in this study for the 86 isolation of viral RNA, as this bodily fluid has demonstrated prolonged presence of viral RNA (up 87 to 25 days post-symptom onset, (11)), irrespective of disease severity (12) . The research 88 protocol (online Methods) was approved by the University of Florida institutional review board. SARS-CoV-2 full-genome (>70%) sequences were successfully generated for five of the 90 vaccinated individuals. A panel of additional respiratory viruses was also targeted during 91 sequencing (Table S2) 95 testing for the majority of these individuals were limited to qualitative data (positive or negative), 96 though the number of PCR cycles (Cq) required for reliable viral RNA amplification for two of the 97 individuals were provided and already >25 at the time of diagnosis (Table S3) , which has been 98 considered relatively high for genomic sequencing (13). Given the time between diagnosis and 99 saliva sampling (Table S1) , saliva viral load may have been too low for the genomic 100 amplification required for amplicon-based sequencing for some individuals. While mutations in 101 primer-binding regions can reduce genome coverage for amplicon-based sequencing (13), . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 coverage mapping did not indicate this phenomenon -alternating regions of high-and lowcoverage were not observed ( Figure S2) . Two of these individuals were, however, genome sequences (Table S2) , supporting the link between severity of symptoms and rapidity In order to understand the context of the vaccine breakthrough infections, we assembled a full- Table S4 . Owing to low genetic 119 variability, as well as potentially shared epidemiological linkages, sequences retrieved from 120 GISAID were often shared by more than one query (Florida) sequence, resulting in a total of spanned October 10, 2020 to March 17, 2021. Lineages for all sequences were determined using the PangoLEARN model (Pangolin v 2.3.6), 125 which was trained using ~60,000 GISAID SARS-CoV-2 sequences to classify incoming 126 sequences based on molecular and epidemiological criteria (2). The full dataset in this study 127 was characterized by a total of 106 lineages, for which only nine (B.1.X) lineages 128 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 represented >99% of samples ( Figure 1A) . The distribution of lineages for Floridian sequences 129 outside of Alachua County largely resembled that of the non-Floridian reference sequences, as 130 expected given the filtering approach for genetic similarity described above; the exception to this 131 similarity was the presence of the B.1.375 lineage within the Florida dataset, which was not 132 present among reference sequences ( Figure 1A) . As this lineage was not observed among the Bootstrap replicates for the sequence data were used to provide support for branching patterns . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The second introduction, estimated to occur in late November, carried a silent mutation from 170 cytosine to thymine within the ORF1ab gene encoding the RNA-dependent RNA polymerase 171 (position 15720 relative to genome start). The expanding virus populations originating from 172 these two events were referred to as "Clade 1" and "Clade 2." Approximately 13% of B.1.1.7 173 individuals within the total Florida sample, and 86% of B.1.1.7 in Alachua County, harbored the belonged to a well-supported clade in this study comprised of five total individuals ( Figure 1D CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 2B) . It was known that the B.1.1.7 vaccination-breakthrough individual (STP-11) 217 was exposed to an infected individual from Orange County, Florida, which suggests a regional is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. harbor infectious virus, the potential for hidden reservoirs within the global populations is 258 increased. Hidden reservoirs in asymptomatic or mild symptomatic individuals, as has been 259 proposed (15), pose a particular threat to early recognition of mutations of potential concern, 260 such as the L18F mutation described herein, particularly once vaccination is more widespread. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.19.21257237 doi: medRxiv preprint 2) The case must meet the definition of a vaccine-breakthrough case or be involved in a 325 cluster of concern and the molecular epidemiology investigation is approved by STP leadership. If both criteria were met and informed consent for the use of the sample for the purpose of Cell culture for viral infectivity. Vero E6 cells were used for SARS-CoV-2 isolation attempts. The cells had been obtained from the American Type Culture Collection (catalog no. ATCC Virologicalorg. 2020;https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-449 sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563. We gratefully acknowledge the following Authors from the Originating laboratories responsible for obtaining the specimens, as well as the References 446 1 Phylogenetic evidence that B.1.1.7 has been circulating in the United Efficacy of the ChAdOx1 461 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Viral dynamics of SARS-CoV-2 in saliva from infected patients Evaluation of NGS-based 478 approaches for SARS-CoV-2 whole genome characterisation SARS-CoV-2, SARS-CoV, and MERS-CoV 480 viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-481 analysis SARS-CoV-2 shifting 483 transmission dynamics and hidden reservoirs limited the efficacy of public health interventions in Italy Spike ∆69/70 sequences (B.1.375) in the United States. Virologicalorg. 487 IQ-490 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era UFBoot2: Improving the Ultrafast 493 Ultrafast approximation for phylogenetic bootstrap Neutralizing and 24. Ostrov D. Structural consequences of variation in SARS-CoV-2 B.1.1. Scientific Archives Antibody resistance of SARS-CoV-2 variants 351 and B.1.1.7. Nature. 2021 Basic local alignment search tool Massively scalable reference-guided multiple sequence alignment of viral 30 Infectious Disease 525 Epidemic: Where We Are, What Can Be Done and Hope For Isolation of 34. CDC. CDC real-time reverse transcriptase PCR (rRT-PCR) diagnostic test for